CADTH Canadian Drug Expert Committee recommendation. Lixisenatide (Adlyxine -- Sanofi-Aventis Canada inc.) : indication : diabetes mellitus, type 2.

CADTH Canadian Drug Expert Committee recommendation. indication : diabetes mellitus, type 2. Lixisenatide (Adlyxine -- Sanofi-Aventis Canada inc.) :

Show other versions (2)

The CADTH Canadian Drug Expert Committee (CDEC) recommends that lixisenatide be reimbursed for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.

Saved in:
Bibliographic Details
Online Access: http://www.ncbi.nlm.nih.gov/books/NBK534071/
Full text
Corporate Author: CADTH Canadian Drug Expert Committee (Author)
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017
Edition:Version 1.0.
Series:Common drug review clinical review report.
Subjects:
Diabetes Mellitus, Type 2 > drug therapy.
Hypoglycemic Agents > therapeutic use.
Peptides > therapeutic use.
Hypoglycemic Agents > economics.
Cost-Benefit Analysis.
Insurance, Health, Reimbursement.
Canada.

Internet

http://www.ncbi.nlm.nih.gov/books/NBK534071/
Full text

Similar Items